Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

A Feature on M&A, VC investment licensing and partnerships focusing on novel targets in autoimmune diseases.

Request To Download Free Sample of This Strategic Report @ Highlighted with 36 tables and 83 figures, this 153-page report ?North America Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

Communications agency Pegasus was given a brief to create an engaging platform capable of improving the understanding of MS and one of Biogen’s products among MS professionals. The result was MS ...

One example is a partnership with French startup Therapanacea around Multiple Sclerosis ... products being developed are effective and easy to use. One example of a patient-facing app in Biogen ...